Formycon Wins Endorsement For Second EU Lucentis Rival

CHMP Positive Opinion For Ranivisio Sets Up Approval For Ranibizumab Biosimilar

 
• By David Wallace
  
EU Flag Eye Close-Up
Formycon’s biosimilar is the second approved EU rival to Lucentis • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products